Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.
暂无分享,去创建一个
Zhaoming Xiong | B. Farmer | Qiang Zhang | J. Proudfoot | N. Moss | N. Farrow | Steven J Taylor | Qiang Zhang | Thomas Neumann | Hans-Dieter Junker | Renate Sekul | Neil Moss | Shuang Liang | Zhaoming Xiong | Melissa Hill-Drzewi | A. Heim-Riether | Shuang Liang | Melissa Hill-Drzewi | Alexander Heim-Riether | Jun Li | T. Neumann | Steven J. Taylor | Donghong Amy Gao | E. Michael August | Brandon K. Collins | Bennett T. Farmer | Kathleen Haverty | S. Mariana Margarit | John R. Proudfoot | Lana Smith Keenan | Neil A. Farrow | H. Junker | R. Sekul | Jun Li | E. Michael August | D. A. Gao | Kathleen Haverty | Lana Smith Keenan | Brandon K Collins | Bennett T Farmer | S. Mariana Margarit | Neil A Farrow | Renate Sekul
[1] T. Rush,et al. Synthesis and SAR of highly selective MMP-13 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[2] C. Rorabeck,et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.
[3] B. G. Rao,et al. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. , 2005, Current pharmaceutical design.
[4] J. Pandit,et al. Potent, selective pyrimidinetrione-based inhibitors of MMP-13. , 2006, Bioorganic & medicinal chemistry letters.
[5] J. Pelletier,et al. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. , 1996, The Journal of clinical investigation.
[6] J. Woessner,et al. Matrix metalloproteinases and TIMPs , 2000 .
[7] A. Parker,et al. Metalloproteinases: their role in arthritis and potential as therapeutic targets , 2003, Expert opinion on therapeutic targets.
[8] Michael R Barnes,et al. Drug discovery in the extracellular matrix. , 2008, Drug discovery today.
[9] A. Freemont,et al. In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage , 1999, Annals of the rheumatic diseases.
[10] K. Geoghegan,et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. , 1996, The Journal of clinical investigation.
[11] E. Kaldjian,et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. , 2003, Arthritis and rheumatism.
[12] K Ulrich Wendt,et al. Structural basis for the highly selective inhibition of MMP-13. , 2005, Chemistry and Biology.
[13] A. Jeng,et al. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. , 2004, Current medicinal chemistry.
[14] T. Cawston,et al. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. , 2006, Best practice & research. Clinical rheumatology.
[15] C. López-Otín,et al. Cellular Mechanisms for Human Procollagenase-3 (MMP-13) Activation , 1996, The Journal of Biological Chemistry.
[16] D. Wernicke,et al. Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. , 1996, The Journal of rheumatology.
[17] Bernard Pirard,et al. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. , 2007, Drug discovery today.
[18] A. Jeng,et al. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. , 2001, Current medicinal chemistry.
[19] Wang Hui,et al. Metalloproteases as potential therapeutic targets in arthritis treatment , 2008, Expert opinion on therapeutic targets.